Phase I and Pharmacokinetic Study of Daily Oral AZD2171, an Inhibitor of Vascular Endothelial Growth Factor Tyrosine Kinases, in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non–Small-Cell Lung Cancer: The National Cancer Institute of Canada Clinical Trials Group
Scott A. Laurie(Ottawa Hospital), Lesley Seymour(Queen's University), Dongsheng Tu(Ontario Institute for Cancer Research), Eric X. Chen(Princess Margaret Cancer Centre), Thomas A. Puchalski(Dana-Farber Cancer Institute), Frances A. Shepherd(University Health Network), Glenwood D. Goss(Ontario Institute for Cancer Research), Wendy Walsh(University of Ottawa), Isabelle Gauthier(University of Ottawa), Jean Powers(University of Ottawa), Jane Robertson(Cancer Research UK), Andrew Arnold(University of Connecticut)
Cited by 120
Related Papers
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
|Journal of Clinical Oncology|2004|2.4k
Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer
|New England Journal of Medicine|2003|2.1k
Cetuximab for the Treatment of Colorectal Cancer
|New England Journal of Medicine|2007|1.8k